Taming “The Monster” – with Koen Sandra - Summary - MDSpire
Advertisement
Taming “The Monster” – with Koen Sandra
Ahead of ISC2026 in Prague, Koen Sandra explores how analytical scientists are rising to the challenge posed by increasingly intimidating biotherapeutics
To discuss the evolution of analytical science in response to increasingly complex biotherapeutics, highlighting its significance in addressing current industry challenges.
Key Findings:
The focus on biopharmaceuticals has evolved from proteins to include nucleic acids and hybrid modalities, impacting analytical approaches.
Analytical scientists face challenges with complex molecules that require advanced analytical techniques, necessitating innovation.
The definition of biopharmaceuticals is inconsistent across regulatory, scientific, and industrial contexts, complicating analysis.
Interpretation:
The term 'biopharmaceuticals' may not adequately encompass the complexity of modern therapeutics, suggesting a need for a broader classification that reflects the diversity of these products.
Limitations:
The definition of biopharmaceuticals lacks universal agreement, complicating regulatory and analytical processes.
Complex molecules often require multiple analytical methods for characterization, such as LC-MS, NMR, and others.
Conclusion:
The landscape of biopharmaceuticals is rapidly changing, necessitating innovative analytical approaches to meet industry demands and address the complexities of modern therapeutics.
Autopsy-confirmed findings linked diagnostic errors, co-pathology, and genetic variation to distinct pathologic patterns across more than 3,300 donors with Parkinsonian disorders.
